|
| Status |
Public on Mar 27, 2024 |
| Title |
DNA methylation in 22Rv1 sgRB1 control |
| Sample type |
SRA |
| |
|
| Source name |
22Rv1
|
| Organism |
Homo sapiens |
| Characteristics |
cell line: 22Rv1
treatment: control
genotype: sgRB1
|
| Growth protocol |
The medium for 22Rv1 cell lines is RPMI-1640 Medium supplumented with 10% fetal bovine serum for 22Rv1 cell line and for PM154 is prostate specific media using advanced DMEM.
|
| Extracted molecule |
genomic DNA |
| Extraction protocol |
Total genomic DNA was extracted from PDXs using QIAamp DNA Mini Kit (QIAGEN).
Illumina
|
| |
|
| Library strategy |
Bisulfite-Seq |
| Library source |
genomic |
| Library selection |
Reduced Representation |
| Instrument model |
Illumina NovaSeq 6000 |
| |
|
| Description |
YY7
|
| Data processing |
restriction enzyme treatment
methylation library preparetion
bisulfite conversion
sequencing
|
| |
|
| Submission date |
Oct 18, 2022 |
| Last update date |
Mar 27, 2024 |
| Contact name |
Yasutaka Yamada |
| E-mail(s) |
yasutaka_yamada@dfci.harvard.edu
|
| Phone |
8574988355
|
| Organization name |
Dana-Farber Cancer Institute
|
| Department |
Medical Oncology
|
| Lab |
Beltran
|
| Street address |
44 Binney street
|
| City |
Boston |
| State/province |
MA |
| ZIP/Postal code |
02115 |
| Country |
USA |
| |
|
| Platform ID |
GPL24676 |
| Series (2) |
| GSE216050 |
DNA methylation as a therapeutic target in RB1 deficient and neuroendocrine prostate cancer and rational co-targeting with B7-H3 [RRBS] |
| GSE216054 |
DNA methylation as a therapeutic target in RB1 deficient and neuroendocrine prostate cancer and rational co-targeting with B7-H3 |
|
| Relations |
| BioSample |
SAMN31357865 |
| SRA |
SRX17947151 |
